News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 73–108
- Matches
- 160
- Sources here
- 17
- Companies here
- 5
Active search
160 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
How Investors Are Reacting To Lindsay (LNN) CFO Transition And Dividend Increase
Lindsay Corporation announced the resignation of its CFO, Sam Hinrichsen, effective August 31, 2026, and simultaneously increased its quarterly dividend to US$0.38 per share. This move signals management's confidence despite a period of softer sales, influencing the investment narrative around balancing growth investment with …
Lindsay Corp's Sam Hinrichsen To Resign As CFO Effective August 31, 2026 - SEC Filing
Lindsay Corp (NYSE: LNN) announced that its Chief Financial Officer, Sam Hinrichsen, will resign from his position effective August 31, 2026. This information was disclosed in a recent SEC filing. No further details regarding the reason for his resignation or a successor were provided …
Lindsay Corporation Announces Resignation of Sam Hinrichsen from Chief Financial Officer, Effective August 31, 2026
Lindsay Corporation announced the resignation of Sam Hinrichsen from his position as Senior Vice President and Chief Financial Officer, effective August 31, 2026. The resignation is for personal reasons and is not related to any disagreements with the company's operations, policies, or accounting practices. …
Lindsay Corporation (NYSE: LNN) CFO to resign, signs paid transition agreement
Lindsay Corporation announced that its Senior Vice President and CFO, Sam Hinrichsen, will resign effective August 31, 2026, for personal reasons. He will provide transition services until December 31, 2026, under a Transition Services Agreement, receiving $100,000 for services, a 2026 annual bonus, and …
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5% - Should You Buy?
Bright Minds Biosciences (NASDAQ:DRUG) shares increased by 5% on Friday, reaching $79.16 with below-average trading volume. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $143.83, and recently surpassed EPS estimates. Insider and institutional ownership remains significant, …
(LNN) Price Dynamics and Execution-Aware Positioning
This article analyzes Lindsay Corporation (LNN) using AI models to provide insights into its price dynamics and positioning. Key findings include a strong near-term sentiment potentially challenging long-term weakness, an exceptional risk-reward setup targeting an 11.7% gain, and detailed trading strategies for various risk …